This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

XBI is trading around $128 with ~$8.06B AUM and ~10M avg daily volume, having risen roughly +58% over the past year and still roughly 45–50 points below its 2021 all-time high. Goldman and Mizuho analysts are bullish for 2026, citing a higher probability of Fed rate cuts (lowering trial financing costs), an expected >15% pickup in biotech M&A, and AI-driven acceleration of drug discovery (2–3 years vs ~10). The ETF’s equal-weight structure increases small-cap biotech exposure and liquidity is ample, but legacy post-pandemic drawdowns and vaccine-related liability disclosures remain downside risks.

Analysis

Mid-stage, Phase II/III asset owners and AI-enabled discovery plays are the asymmetric winners if rate cuts and cheaper capital actually materialize over the next 6–18 months; these names will see both higher takeout appetite and meaningfully cheaper trial financing that compresses time to value. Expect outsized returns from companies with single, de-risked catalysts (readouts or filing-ready programs) rather than broad platform stories — a successful readout or announced auction process typically generates 50–150% jumps in small-cap biotechs within 1–3 months.

Second-order effects tilt toward service providers and constrained manufacturing niches: CDMOs, isotope suppliers for radiopharma, and specialized CROs will see demand ahead of acquirers completing deals, creating an intermediate liquidity play separate from drug value. Conversely, legacy large-cap vaccine and infectious disease franchises carry an idiosyncratic liability and reputational overhang that can limit bid-side interest and make them suboptimal hedges for a biotech rally.

Principal risks are timing and binary clinical outcomes — a Fed hold or inflation resurgence can compress biotech multiples within weeks, while one high-profile safety story could reprice small-cap risk premia across the sector. The consensus underestimates both how slowly AI converts to revenue (2–5 years) and how much ETF equal-weight mechanics amplify drawdowns on index reconstitution days; structured, event-driven positions with capped downside are preferable to outright long passive exposure right now.

Key Decisions for Investors

• Long concentrated event-driven basket (ROIV, PCVX, ACLX, PRAX, RVMD) — equal-weight, size 3–5% portfolio. Express via 9–12 month call spreads (buy 1x 30–40% OTM calls / sell 1x 60–80% OTM calls) to cap premium outlay; objective 2.5–4.0x payout if one or two targets clear Phase II/III or enter auction within 6–12 months. Max loss = premium paid (~1–3% portfolio per spread).
• Pair trade: Long small-cap biotech basket (as above) vs short MRNA + GILD — reduce net market-beta by 40–60%. Implement by buying puts on the small-cap basket replacement (protective puts) while buying 6–9 month deep OTM puts on MRNA and GILD (or short the stocks size 50% of long notional). Target 1.5–2x risk-adjusted return if small-cap M&A accelerates while legacy names face liability/volume pressure; hedge cost ~0.5–1% portfolio.
• Tactical ETF play: Modest long XBI exposure via 6-month bull call spread (buy 10–15% OTM / sell 30–40% OTM) sized 1–2% portfolio to capture a rate-cut rally without open-tail downside. Exit or roll at major Fed meetings or after large sector readouts; expected return 1.5–3x if sector momentum continues, max loss = premium.
• Event-speculative short: Initiate small, time-limited short or buy puts on vaccine/legacy exposure (MRNA, GILD, GSK) sized to 25–40% of long small-cap exposure to exploit liability/reputation risk. Use 3–9 month options to limit duration risk; plan to cover on definitive benign regulatory clarity or major M&A headlines.